Here are the 10-K annual reports from Abeona Therapeutics Inc. (ABEO) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ABEO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ABEO filings page.
Abeona Therapeutics Inc. is now a commercial-stage cell and gene therapy company following U.S. FDA approval of ZEVASKYN® on April 28, 2025 for treating wounds in adults and children with recessive dystrophic epidermolysis bullosa (RDEB), a severe genetic skin disease with no cure.
ZEVASKYN® is the first and only FDA-approved autologous cell-based gene therapy for RDEB wounds and is manufactured at Abeona’s cGMP facility in Cleveland, Ohio. As of March 2026, four qualified U.S. treatment centers are activated, and the company has broad commercial and Medicaid coverage plus a permanent J‑code effective January 1, 2026.
The company sold a Rare Pediatric Disease Priority Review Voucher for $155.0 million, strengthening its cash position, and estimates about 750 moderate-to-severe RDEB patients in the U.S. could be eligible for ZEVASKYN®. Abeona is also advancing AAV-based gene therapies for XLRS (ABO‑503), Stargardt disease (ABO‑504), and ADOA (ABO‑505) using its AIM™ capsid platform and has multiple out‑licensing and capsid-licensing deals supporting additional milestone and royalty potential.